Systemic therapy for moderate-to-severe psoriasis

References

• Andressen C, Heuseler T. Inheritance of psoriasis. Analysis of 2035 family histories. Hautarzt 33, 214–217 (1982).
   PubMed Web of Science ®Google Scholar
• Norholm-Pederson A. Infections and psoriasis. Acta Derm. Venereol. 32, 159–167 (1962).
   Google Scholar
• Skov L, Baadgaard O. Bacterial superantigens and inflammatory skin diseases. Clin. Exp. Dermatol. 25(1), 57–61 (2000).
   PubMed Web of Science ®Google Scholar
• Gupta MA, Gupta AK, Kirby S. A psychocutaneous profile of psoriasis patients who are stress reactors. Gen. Hosp. Psychiatry 11, 166–173 (1989).
   PubMed Web of Science ®Google Scholar
• Tsankov N, Angelova I, Kazandjieva R. Drug-induced psoriasis. Recognition and management. Am. J. Clin. Dermatol. 1, 159–165 (2000).
   PubMedGoogle Scholar
• Farber E, Bright R, Nall M. Psoriasis: a questionnaire survey of 2144 patients. Arch. Dermatol. 98, 248–259 (1968).
   PubMedGoogle Scholar
• Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin. Exp. Dermatol. 26, 314–320 (2001).
   PubMed Web of Science ®Google Scholar
• Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J. Am. Acad. Dermatol. 13, 450–456 (1985).
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. 41(3 Pt 1), 401–407 (1999).
   PubMed Web of Science ®Google Scholar
• Finlay AY. Quality of life assessments in Dermatol. Semin. Cutan. Med. Surg. 17, 291–296 (1998).
   Google Scholar
• McKenna KE, Stern RS. The outcomes movement and new measures of severity of psoriasis. J. Am. Acad. Dermatol. 34, 534–538 (1996).
   PubMed Web of Science ®Google Scholar
• Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE. Quality of life measures in psoriasis: a critical appraisal of their quality. J. Clin. Pharm. Ther. 23, 391–398 (1998).
   PubMed Web of Science ®Google Scholar
• Rapp SR, Exum ML, Reboussin DM et al. The physical, psychological, and social impact of psoriasis. J. Health Psychol. 2, 525–537 (1997).
   PubMedGoogle Scholar
• Krueger G, Feldman SR, Camisa C et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J. Am. Acad. Dermatol. 43, 281–285 (2000).
   PubMed Web of Science ®Google Scholar
• Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Flow cytometric identification of proliferative subpopulations within normal human epidermis and the localization of the primary hyperproliferative population in psoriasis. J. Exp. Med. 178, 1271–1281 (1993).
   PubMed Web of Science ®Google Scholar
• Nanney LB, Stoscheck CM, Magid M, King IJ. Altered (125I) epidermal growth factor binding and receptor distribution in psoriasis. J. Invest. Dermatol. 86, 260–265 (1986).
   PubMed Web of Science ®Google Scholar
• Krane JF, Gottlieb AB, Carter DM, Krueger JG. The insulin-like growth factor I receptor is overexpressed in psoriatic epidermis, but is differentially regulated from the epidermal growth factor receptor. J. Exp. Med. 175, 1081–1090 (1992).
   PubMedGoogle Scholar
• Mueller W, Herrmann B. Cyclosporin A for psoriasis. N. Engl. J. Med. 301, 555 (1979).
   PubMed Web of Science ®Google Scholar
• Gilhar A, David M, Ullmann Y, Berkutski T, Kalish RS. T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice. J. Invest. Dermatol. 109, 283–288 (1997).
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Matsuuchi M, Katayama I, Nishioka K. Repeated subcutaneous injection of staphylococcal enterotoxin B-stimulated lymphocytes retains epidermal thickness of psoriatic skin-graft onto severe combined immunodeficient mice. J. Dermatol. Sci. 17, 8–14 (1998).
   PubMed Web of Science ®Google Scholar
• Ellis CN, Gorskulowsky DC, Hamilton TA et al. Cyclosporin improves psoriasis in a double-blind study. JAMA 256, 3110–3116 (1986).
   PubMed Web of Science ®Google Scholar
• Gottlieb SL, Gilleaudeau P, Johnson R et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med. 1, 442–447 (1995).
   PubMed Web of Science ®Google Scholar
• Krueger JG. The immunologic basis for the ••treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. 46, 1–23 (2002).
   PubMed Web of Science ®Google Scholar
• Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin αEβ7 in the pathogenesis of psoriasis vulgaris. Lab. Invest. 81, 335–347 (2001).
   PubMed Web of Science ®Google Scholar
• Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM. CD69, HLA-DR and the IL-2R identify persistently activated T-cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J. Autoimmun. 14, 63–78 (2000).
   PubMed Web of Science ®Google Scholar
• Bonish B, Jullien D, Dutronc Y et al. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-γ production by NK-T cells. J. Immunol. 165(7), 4076–4085 (2000).
   PubMed Web of Science ®Google Scholar
• Strange P, Cooper KD, Hansen ER et al. T-lymphocyte clones initiated from lesional psoriatic skin release growth factors that induce keratinocyte proliferation. J. Invest. Dermatol. 101, 696–700 (1993).
   Google Scholar
• Capon F, Munro M, Barker J, Trembath R. Searching for the major histocompatibility complex psoriasis susceptibility gene. J. Invest. Dermatol. 118, 745–751 (2002).
   PubMed Web of Science ®Google Scholar
• Shenolikar S, Weinman EJ. NHERF: targeting and trafficking membrane proteins. Am. J. Physiol. 280, F389–F395 (2001).
   Google Scholar
• Voltz JW, Weinman EJ, Shenolikar S. Expanding the role of NHERF, a PDZ-domain containing protein adapter, to growth regulation. Oncogene 20, 6309–6314 (2001).
   PubMedGoogle Scholar
• Weinman EJ. New functions for the NHERF family of proteins. J. Clin. Invest. 108, 185–186 (2001).
   PubMedGoogle Scholar
• Itah K, Sakakibara M, Yamasaki S et al. Cutting edge: negative regulation of immune synapse formation by anchoring lipid raft to cytoskeletin through Cbf-EBP50-ERM assembly. J. Immunol. 168, 541–544 (2002).
   PubMedGoogle Scholar
• Tomfohrde J, Silverman A, Barnes R et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 264, 1141–1145 (1994).
   PubMed Web of Science ®Google Scholar
• Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T-cells. J. Clin. Invest. 102, 322–328 (1998).
   PubMed Web of Science ®Google Scholar
• Van de Kerkhof PCM, Bauer FW, Maassen-de Grood RM. Methotrexate inhibits the leukotriene B4-induced accumulation of polymorphonuclear leukocytes. Br. J. Dermatol. 113, 251–255a (1985).
   Google Scholar
• Lammers AM, van de Kerkhof PC, Mier PD. Reduction of leukotriene B4-induced intraepidermal accumulation of polymorphonuclear leukocytes by methotrexate in psoriasis. Br. J. Dermatol. 116, 667–671 (1987).
   PubMedGoogle Scholar
• Ternowitz T, Bjerring P, Andersen PH, Schroder JM, Kragballe K. Methotrexate inhibits the human C5a-induced skin response in patients with psoriasis. J. Invest. Dermatol. 89, 192–196 (1987).
   PubMedGoogle Scholar
• Crostein BN, Levin RI, Belanoff J, Weissmann G, Hirschhorn R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J. Clin. Invest. 78, 760–770 (1986).
   PubMedGoogle Scholar
• Cronstein BN, Levin RI, Philips M, Hirschhorn R, Abramson SB, Weissmann G. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J. Immunol. 148, 2201–2206 (1985).
   Google Scholar
• Thiel M, Choker A. Acting via A2 receptors, adenosine inhibits the production of tumor necrosis factor-a of endotoxin-stimulated human polymorphonuclear leukocytes. J. Lab. Clin. Med. 126, 275–282 (1995).
   PubMed Web of Science ®Google Scholar
• Bolognia JL, Jorizzo JL, Rapini RP. Dermatology (Vol 1). Psoriasis. Mosby, London, UK, 125–149 (2003).
   Google Scholar
• Said S, Jeffes EWB, Weinstein GD. Systemic treatment, methotrexate. Clin. Dermatol. 15, 781–796 (1997).
   PubMed Web of Science ®Google Scholar
• Van de Kerkhof PCM, Mali JWH. Methotrexate maintenance following ingram therapy in difficult psoriasis. Br. J. Dermatol. 106, 623–627 (1982).
   PubMedGoogle Scholar
• Malatjalian DA, Ross JB, Williams CN, Colwell SJ, Eastwood BJ. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis or risks from obesity, diabetes, and alcohol consumption during long-term follow-up. Can. J. Gastroenterol. 10, 369–375 (1996).
   PubMedGoogle Scholar
• Van Dooren-Greebe RJ, Kuijpers ALA, Buijs WCAM et al. The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of Type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients. Br. J. Dermatol. 134, 481–487 (1996).
   PubMed Web of Science ®Google Scholar
• Zachariae J, Heickendorff L, Sogaard J. The value of aminoterminal propeptide of Type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br. J. Dermatol. 143, 100–103 (2001).
   Google Scholar
• Saporito FC, Menter MA. Methotrexate ••and psoriasis in the era of new biologic agents. J. Am. Acad. Dermatol. 50, 301–309 (2004).
   PubMed Web of Science ®Google Scholar
• Wong RL, Winslow CM, Cooper KD. The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunol. Today 14, 69–73 (1993).
   PubMedGoogle Scholar
• Baker BS, Griffiths CEM, Lambert S et al. The effect of cyclosporin A on T-lymphocyte and dendritic cell subpopulations in psoriasis. Br. J. Dermatol. 116(4), 503–510 (1987).
   PubMed Web of Science ®Google Scholar
• Nozzanica N. Pigato PD, Finzi AF. Cyclosporin in psoriasis: pathophysiology and experimental data. Dermatologica 187(Suppl. 1), 3–7 (1993).
   Google Scholar
• Demidem A, Taylor IR, Grammer SF, Streilein JW. T-lymphocyte-activating properties of antigen-presentating cells from normal psoriatic skin: evidence that psoriatic epidermal antigen-presenting cells resemble cultured normal Langerhans cells. J. Invest. Dermatol. 97, 454–460 (1991).
   PubMedGoogle Scholar
• Griffiths CE, Dubertret L, Ellis CN et al. ••Ciclosporin in psoriasis clinical practice: an international consensus statement. Br. J. Dermatol. 150(Suppl. 67), 11–23 (2004).
   PubMed Web of Science ®Google Scholar
• Heydendael VM, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporin in moderate-to-severe chronic plaque psoriasis. N. Engl. J. Med. 349(7), 658–665 (2003).
   PubMed Web of Science ®Google Scholar
• Tristani-Firouzi P, Krueger GG. Efficacy and safety of treatment modalities for psoriasis. Cutis 61(Suppl.), 11–21 (1998).
   PubMed Web of Science ®Google Scholar
• Gollnick HP, Dummler U. Retinoids. Clin. Dermatol. 15, 799–810 (1997).
   PubMed Web of Science ®Google Scholar
• Kuenzli S, Saurat J. Retinoids for the treatment of psoriasis: outlook for the future. Curr. Opin. Invest. Drugs. 2(5), 625–629 (2001).
   PubMedGoogle Scholar
• Lee E, Koo J. Single-center retrospective study of long-term use of low-dose acitretin (Soriatane) for psoriasis. J. Dermatol. Treat. 15(1), 8–13 (2004).
   PubMedGoogle Scholar
• Mrowietz U, Christopher E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German fumaric acid ester consensus conference. Br. J. Dermatol. 141, 424–429 (1999).
   PubMed Web of Science ®Google Scholar
• Treumer F, Zhu K, Glaser R et al. Dimethylfumarate is a potent inducer of apoptosis in human T-cells. J. Invest. Dermatol. 121, 1383–1388 (2003).
   PubMed Web of Science ®Google Scholar
• Nugteren-Huying WM, van der Schroeff JG, Jermans J et al. Fumaric acid therapy for psoriasis: a randomized, double-blind, placebo-controlled study. J. Am. Acad. Dermatol. 22, 311–312 (1990).
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Chrostopher E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German multicentre study. Br. J. Dermatol. 138, 456–460 (1998).
   PubMed Web of Science ®Google Scholar
• Naldi L, Griffiths CEM. Traditional therapies ••in the management of moderate to severe chronic plaque psoriasis: an assessment of benefits and risks. Br. J. Dermatol. 152(4), 597–615 (2005).
   PubMed Web of Science ®Google Scholar
• Friedrich M, Sterry W, Klein A et al. Addition of pentoxifylline could reduce the side effects of fumaric acid esters in the treatment of psoriasis. Acta Derm. Venereol. 81, 429–430 (2001).
   PubMed Web of Science ®Google Scholar
• Haranaka K, Carswell EA, Williamson BD, Prendergast JS, Satomi M, Old LJ. Purification, characterization, and antitumor activity of nonrecombinant mouse tumor necrosis factor. Proc. Natl Acad. Sci. USA 83, 3949–3953 (1986).
   PubMedGoogle Scholar
• Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumor necrosis factor-α (TNF-α) biological activity in psoriatic skin lesions. Clin. Exp. Immunol. 96, 146–151 (1994).
   PubMed Web of Science ®Google Scholar
• Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T-cells in psoriasis vulgaris lesions can produce Type 2 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1(cytotoxic T-lymphocyte) and TH1 effector populations: a Type 1 differentiation bias is also measured in circulating blood T-cells in psoriatic patients. J. Invest. Dermatol. 13, 752–759 (1999).
   Google Scholar
• Mizutani H, Onmoto Y, Mizutani T, Murata M, Shimizu M. Role of increased production of monocytes TNF-α, IL-1β and IL-6 in psoriasis: relation to focal infection, disease activity, and response to treatments. J. Dermatol. Sci. 14, 145 (1997).
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J. Rheumatol. 25, 1544–1552 (1998).
   PubMed Web of Science ®Google Scholar
• Kimber I, Cumberbatch M, Dearman RJ, Bhushan M, Griffiths CEM. Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization. Br. J. Dermatol. 142, 401–412 (2000).
   PubMed Web of Science ®Google Scholar
• Xia AY, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS. Transgenic delivery of VEFG to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102(1), 161–168 (2003).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Lowe N et al. ••A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol. 139(12), 1627–1632 (2003).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, Vander-Stoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356(9227), 385–390 (2000).
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers IL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349(21), 2014–2022 (2003).
   PubMed Web of Science ®Google Scholar
• Leonardi C, Gottlieb AB, Zitnik R. Efficacy and safety of Enbrel in patients with psoriasis: results of a Phase 3 study. J. Investig. Dermatol. 120(7), 4–30 (2003).
   Google Scholar
• Tyring S, Poulin Y, Langley R, Gordon K, Jahreis A. A 2-year Phase 3 study of safety and efficacy of etanercept 50 mg twice weekly in patients with psoriasis: 48-week results. Presentation at: 63rd Annual Meeting of American Academy of Dermatology. IL, USA, 20–24 July (2005).
   Google Scholar
• Knight D, Trinh H, Le J et al. Construction and initial characterization of a mouse-human chimeric antiTNF antibody. Mol. Immunol. 30, 1443–1453 (1993).
   PubMed Web of Science ®Google Scholar
• Callon BJ, Moore MA, Trinh H, Knight DM, Grayeb J. Chimeric antiTNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7, 251–259 (1995).
   PubMedGoogle Scholar
• Ten Hove T, Van Montfrans C, Peppelenbosch MP, Van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T-lymphocytes in Crohn’s disease. Gut 50, 206–211 (2002).
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357, 1842–1847 (2001).
   PubMed Web of Science ®Google Scholar
• Feldman SR, Gordon KB, Bala M et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br. J. Dermatol. 152, 954–960 (2005).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Feldman S, Weinstein G, Menter A. Infliximab Phase III results: every 8 week versus as needed maintenance therapy. Presented at: American Academy of Dermatology Summer Conference. IL, USA 20–24 July (2005).
   Google Scholar
• Reich K, Nestle F, Papp K et al. Infliximab induction and maintenance therapy for moderate to severe psoriasis: a Phase III, multicenter, double-blind trial. Lancet 366, 367–374 (2005).
   PubMedGoogle Scholar
• Menter M, Gordon K, Leonardi C, Hoffman R. Adalimumab efficacy and safety results in patients with moderate to severe chronic plaque psoriasis with and without psoriatic arthritis. Presented at: The 63rd Annual Meeting of American Academy of Dermatology, IL, USA, 18–22 February (2005).
   Google Scholar
• Winterfield LS, Menter A. Infliximab. ••Dermatol. Ther. 17(5), 409–426 (2004).
   PubMedGoogle Scholar
• Keystone EC. Safety of biologic therapies – an update. J. Rheumatol. 32(Suppl. 74), 8–12 (2005).
   Web of Science ®Google Scholar
• Bergstrom L, Yocum DE, Ampel NM et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists. Arthritis Rheum. 50, 1959–1966 (2004).
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Update on the TNF-α blocking agents. Presented at a meeting of the Arthritis Advisory Committee, March 4 (2003) (FDA Briefing Document).
   Google Scholar
• Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch. Dermatol. 139(11), 1425–1429 (2003).
   PubMed Web of Science ®Google Scholar
• Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor-necrosis factor-α in the adult mammalian heart. J. Clin. Invest. 92, 2303–2312 (1993).
   PubMed Web of Science ®Google Scholar
• Chung ES, Packer M, Lo KH, Fascenmade AA, Willerson JT. Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized double-blind, placebo-controlled pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate to severe heart failure: results of the antiTNF therapy against congestive heart failure (ATTACH) trial. Circulation 107, 3133–3140 (2003).
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud MS. Congestive heart failure in rheumatoid arthritis: rates, predictors and the effect of antiTNF therapy. Am. J. Med. 116, 305–311 (2004).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Jaunatey C, Testa A, Garcia-Castelo A, Llocca J, Gonzalez-Gay MA. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with antitumor necrosis factor α therapy. Arthritis Rheum. 51, 447–450 (2004).
   PubMedGoogle Scholar
• Voelker R. New heart failure guidelines released. JAMA 294, 892 (2005).
   PubMedGoogle Scholar
• van Oosten BW, Barkhof F, Truyen L et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal antitumor necrosis factor antibody cA2. Neurology 47, 1531–1534 (1996).
   PubMed Web of Science ®Google Scholar
• Sarzi-Puttini P, Ardizzone S, Mangionna G et al. Infliximab-induced lupus in Crohn’s disease: a case report. Dig. Liver Dis. 35(11), 814–817 (2003).
   PubMedGoogle Scholar
• Vermeire S, Noman M, Van Assche G et al. Autoimmunity associated with antiTNF-α therapy in Crohn’s disease: a prospective cohort study. Gastroenterol. 125(1), 32–39 (2003).
   PubMed Web of Science ®Google Scholar
• Cheifetz A, Smedley M, Martin S et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am. J. Gastroenterol. 98, 1315–1324 (2003).
   PubMed Web of Science ®Google Scholar
• Krueger GG, Callis KP. Development and ••use of alefacept to treat psoriasis. J. Am. Acad. Dermatol. 49(2 Suppl.), S87–S97 (2003).
   PubMed Web of Science ®Google Scholar
• Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-ig fusion proteins inhibition of T-cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J. Immunol. 152, 2753–2767 (1994).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Casale TB, Frankel E et al. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J. Am. Acad. Dermatol. 49, 816–825 (2003)
   PubMed Web of Science ®Google Scholar
• Ellis CN, Krueger GG. Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T-lymphocytes. N. Engl. J. Med. 345, 248–255 (2001).
   PubMed Web of Science ®Google Scholar
• Chamian F, Lowes M, Lin S et al. Alefacept reduces infiltrating T-cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc. Natl Acad. Sci. USA 102(6), 2075–2080 (2005).
   PubMed Web of Science ®Google Scholar
• Vaishnaw AK, TenHoor CN. Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J. Pharmacokinet. Pharmacodyn. 29, 415–426 (2002).
   PubMed Web of Science ®Google Scholar
• Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN (Alefacept Clinical Study Group). A randomized, double-blind, placebo-controlled Phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J. Am. Acad. Dermatol. 47, 821–833 (2002).
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE (Alefacept Clinical Study Group). An international, randomized, double-blind, placebo-controlled Phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch. Dermatol. 139, 719–727 (2003).
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. J. Drugs Dermatol. 2, 624–628 (2003).
   PubMedGoogle Scholar
• Krueger GG, Ellis CN. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br. J. Dermatol. 148, 784–788 (2003).
   PubMed Web of Science ®Google Scholar
• AMEVIVE® (alefacept), package insert. Biogen Idec Inc. USA. (2005).
   Google Scholar
• Hodak E, David M. Alefacept: a review of the literature and practical guidelines for management. Dermatol. Ther. 17, 383–392 (2004).
   PubMedGoogle Scholar
• Gribetz CH, Blum R, Brady C, Cohen S, Lebwohl M. Safety and efficacy of an extended 16-week course of alefacept in the treatment of chronic plaque psoriasis: an interim analysis. Presentation at: 62nd Annual Meeting of the American Academy of Dermatology. WA, USA, February (2004).
   Google Scholar
• Bagel J. Efficacy and safety of multiple courses of alefacept in combination with UVB light and other psoriasis therapies. Presentation at: The American Academy of Dermatology, IL, USA, July (2005).
   Google Scholar
• Lebwohl M, Menter A. Efficacy and safety of alefacept in combination with methotrexate in the treatment of psoriatic arthritis. Presentation at: The American Academy of Dermatology, IL, USA, July (2005).
   Google Scholar
• Werther WA, Gonzalez TN, O’Connor SJ et al. Humanization of an antilymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J. Immunol. 157, 4986–4995 (1996).
   PubMed Web of Science ®Google Scholar
• Leonardi CL. Efalizumab in the treatment of psoriasis. Dermatol. Ther. 17, 393–400 (2004).
   PubMedGoogle Scholar
• Dedrick RL, Walicke P, Garovoy M. Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody. Transpl. Immunol. 9, 181–186 (2002).
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Krueger JG, Bright R et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J. Am. Acad. Dermatol. 42, 428–435 (2000).
   PubMed Web of Science ®Google Scholar
• Gordon KB, Papp KA, Hamilton TK et al. Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290(23), 3073–3080 (2003).
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring SK, Hamilton TK et al., Efalizumab Study Group. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. 349, 2004–2013 (2003).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Gordon KB, Lebwohl MG et al. Efalizumab Study Group. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J. Drugs Dermatol. 3, 614–624 (2004).
   PubMedGoogle Scholar
• Leonardi CL, Papp KA, Gordon KB et al. Efalizumab Study Group. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized Phase III trial. J. Am. Acad. Dermatol. 52(3), 425–433 (2005).
   PubMed Web of Science ®Google Scholar
• Genentech Inc. Raptiva™ (efalizumab) package insert. CA, USA, July (2005).
   Google Scholar
• Lebwohl M, Menter A, Koo J, Feldman S. Case studies in severe psoriasis: a clinical strategy. J. Dermatol. Treat. 14, 26–46 (2003).
   PubMedGoogle Scholar
• Menter A, Hamilton T, Caro I, Rundle AC, Koo J. Impact of efalizumab on patient-reported outcomes in patients with chronic moderate to severe plaque psoriasis: pooled results from three randomized Phase III trials. Presented at: 63rd Annual Meeting of The American Academy of Dermatology, IL, USA, July (2005).
   Google Scholar
• Menter A, Gordon K, Carey W et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch. Dermatol. 141, 31–38 (2005).
   PubMed Web of Science ®Google Scholar
• Menter A, Hamilton T, Caro I, Kwon P, Compton P, Papp K. Safety and tolerability of efalizumab therapy for patients with moderate to severe chronic plaque psoriasis: results of an open-label Phase IIIb multicenter trial. Presented at: 63rd Annual Meeting of The American Academy of Dermatology. IL, USA, July (2005).
   Google Scholar
• Gottlieb A, Gordon K, Hamilton T et al. Maintenance of efficacy and safety with continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: final Phase IIIb study results.
   Google Scholar
• Cather JC, Menter A. Efalizumab: continuous therapy for chronic psoriasis. Expert Opin. Biol. Ther. 5, 393–403 (2005).
   PubMed Web of Science ®Google Scholar
• Menter A, Kardatzke D, Rundle A, Kwon P, Garovoy M, Leonardi C. Incidence and prevention of rebound upon efalizumab discontinuation. Presentation at: 63rd Annual Meeting of The American Academy of Dermatology. IL, USA, July (2005).
   Google Scholar
• Kauffman CL, Aria N, Toichi E et al. A Phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol. 123(6), 1037–1044 (2004).
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature Rev. Immunol. 3(2), 133–146 (2003).
   PubMed Web of Science ®Google Scholar
• Leung DYM, Gately M, Trumble A et al. Bacterial superantigens induce T-cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interleukin-12 production. J. Exp. Med. 181, 747–753 (1995).
   PubMed Web of Science ®Google Scholar
• Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR. Expression of interleukin-12 is increased in Pporiatic skin. J. Invest. Dermatol. 111(6), 1053–1057 (1998).
   PubMed Web of Science ®Google Scholar
• Lee E, Trepicchio WL, Oestreicher JL et al. Increased expression of interleukin-23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199(1), 125–130 (2004).
   PubMed Web of Science ®Google Scholar
• Nestle FO, Conrad C. The IL-12 Family member p40 chain as a master switch and novel therapeutic target in psoriasis. J. Invest. Dermatol. 123(6), xiv–xv (2004).
   PubMed Web of Science ®Google Scholar
• Langley R, Lebwohl M, Leonardi C et al. Results of a Phase II study of a human anti-interleukin (IL)-12/IL-23 monoclonal antibody in the treatment of psoriasis. Presented at: Annual Meeting of The Society for Investigative Dermatology. MO, USA, May (2005).
   Google Scholar
• Lankford CS, Frucht DM. A unique role for IL-23 in promoting cellular immunity. J. Leukoc. Biol. 73(1), 49–56 (2003).
   PubMed Web of Science ®Google Scholar